SCM
ASND icon

Spyglass Capital Management’s Ascendis Pharma A/S ASND Stock Holding History

Spyglass Capital Management’s Portfolio ASND Stock Details ASND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$57.5M Sell
215,398
-152,574
-41% -$35.6M 3.11% 20
2026
Q1 		$84.2M Sell
367,972
-47,577
-11% -$10.7M 5.96% 2
2025
Q4 		$88.6M Buy
415,549
+26,902
+7% +$5.56M 4.43% 8
2025
Q3 		$77.3M Buy
+388,647
New +$72.5M 4.12% 14
2024
Q4 		– Sell
-652,841
Closed -$97.5M – 26
2024
Q3 		$97.5M Sell
652,841
-10,047
-2% -$1.36M 6.4% 2
2024
Q2 		$90.4M Buy
662,888
+48,781
+8% +$6.64M 6.62% 1
2024
Q1 		$92.8M Buy
614,107
+74,159
+14% +$10.6M 6.18% 2
2023
Q4 		$68M Sell
539,948
-74,670
-12% -$7.44M 4.89% 2
2023
Q3 		$57.6M Sell
614,618
-43,235
-7% -$4.04M 4.51% 9
2023
Q2 		$58.7M Sell
657,853
-56,113
-8% -$4.88M 4.24% 11
2023
Q1 		$76.6M Sell
713,966
-495
-0.1% -$56.6K 5.77% 2
2022
Q4 		$87.3M Sell
714,461
-235,454
-25% -$27.3M 7.01% 1
2022
Q3 		$98.1M Sell
949,915
-159,755
-14% -$15.1M 6.94% 1
2022
Q2 		$103M Sell
1,109,670
-94,320
-8% -$8.89M 5.73% 3
2022
Q1 		$141M Sell
1,203,990
-107,925
-8% -$12.5M 4.83% 8
2021
Q4 		$176M Sell
1,311,915
-66,972
-5% -$9.96M 4.68% 8
2021
Q3 		$220M Buy
1,378,887
+256,216
+23% +$35.1M 5.04% 6
2021
Q2 		$148M Buy
1,122,671
+151,566
+16% +$20.2M 3.29% 16
2021
Q1 		$125M Buy
971,105
+269,511
+38% +$41M 3.3% 18
2020
Q4 		$117M Buy
701,594
+154,572
+28% +$25.6M 3.59% 17
2020
Q3 		$84.4M Buy
547,022
+94,918
+21% +$13.6M 3.9% 14
2020
Q2 		$66.9M Buy
452,104
+100,716
+29% +$13.8M 4.14% 12
2020
Q1 		$39.6M Buy
351,388
+100,416
+40% +$13M 4.47% 11
2019
Q4 		$34.9M Buy
250,972
+117,283
+88% +$13M 4.48% 10
2019
Q3 		$12.9M Buy
133,689
+22,949
+21% +$2.56M 3.42% 17
2019
Q2 		$12.8M Buy
110,740
+20,675
+23% +$2.47M 4.03% 13
2019
Q1 		$10.6M Buy
90,065
+47,000
+109% +$4.12M 4.1% 14
2018
Q4 		$2.7M Buy
+43,065
New +$2.71M 2.02% 25

Other funds holding ASND

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Spyglass Capital Management's ASND Position: Q2 2026 in Review

Spyglass Capital Management reduced its Ascendis Pharma A/S (ASND) stake by 41% in Q2 2026, selling an estimated $35.6M and leaving 215,398 shares worth $57.5M. The position accounts for 3.11% of the portfolio, ranked #20.

Spyglass Capital Management first reported a position in ASND in Q4 2018 and has held it in 28 quarters since. The position peaked at $220M in Q3 2021. 313 funds tracked by Wall St. Rank hold ASND as of Q2 2026.

  • Spyglass Capital Management held 215,398 shares of Ascendis Pharma A/S worth $57.5M as of Q2 2026.
  • Spyglass Capital Management sold 152,574 Ascendis Pharma A/S shares in Q2 2026, an estimated $35.6M.
  • Ascendis Pharma A/S made up 3.11% of Spyglass Capital Management's portfolio in Q2 2026, its #20 holding.
  • Spyglass Capital Management first reported a position in Ascendis Pharma A/S in Q4 2018 and has held it in 28 quarters since.
  • Spyglass Capital Management's Ascendis Pharma A/S position peaked at $220M in Q3 2021.
  • 313 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q2 2026.

Based on Spyglass Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.